Mon panier

Biotinylated Human Integrin alpha V beta 1 (ITGAV&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
IT1-H82W6-25ug
$415.00
IT1-H82W6-200ug
$1880.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    Integrin alpha V beta 1, ITGAV&ITGB1

  • Source

    Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (IT1-H82W6) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gln 21 - Asp 728 (ITGB1) (Accession # NP_002201.1 (ITGAV) & NP_002202.2 (ITGB1)).

    Predicted N-terminus: Phe 31 (ITGAV) & Gln 21 (ITGB1)

    Request for sequence
  • Molecular Characterization

    Integrin alpha V beta 1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB1, has a calculated MW of 114.7 kDa (ITGAV) and 83.7 kDa (ITGB1). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB1 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 135-150 kDa (ITGAV) and 100-115 kDa (ITGB1) respectively due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    Integrin alpha V beta 1 SDS-PAGE

    Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     Integrin alpha V beta 1 ELISA

    Immobilized Fibronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB1 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT1-H82W6) with a linear range of 0.039-0.625 μg/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Integrin alpha-5/beta-1 is a receptor for ibrinogen. Integrin alpha-1/beta-1, alpha-2/beta-1, alpha-6/beta-1 and alpha-7/beta-1 are receptors for lamimin. Integrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. It recognizes the sequence A-E-I-D-G-I-E-L in cytotactin. Integrin alpha-V/beta-1 is also a receptor for vitronectin. Beta-1 integrins recognize the sequence R-G-D in a wide array of ligands. Isoform 2 interferes with isoform 1 resulting in a dominant negative effect on cell adhesion and migration (in vitro). When associated with alpha-7/beta-1 integrin, regulates cell adhesion and laminin matrix deposition.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Integrin alpha-V/beta-1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    5 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte